SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-06103

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
PRIVACY	NICARAGUA	18	Apr	2017	8	Female	23	May	2025	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Frequent mood swings (Altered mood (10001850), Mood altered (10027940))
(/Jul/2025 -) - Not Recovered/Not Resolved/Ongoing
2) 8-year-old female patient being treated with Eligard 22.5mg for 3 months for precocious puberty (Off label use in unapproved indication (10084345), Off label use (10053762))
(23/May/2025 -) - Unknown

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION
1) (22.5 milligram(s), 1 in 3 Month) (22.5 milligram(s))	1) Subcutaneous 2) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Precocious puberty [10058084 - Precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (23/May/2025 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PRECOCIOUS PUBERTY (10058084, Precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1-9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-06103
24c. DATE RECEIVED BY MANUFACTURER 22/Aug/2025	24d. REPORT SOURCE ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT 26/Aug/2025	25a. REPORT TYPE ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium via "ASOFARMA A TU LADO" Patient Support Programme (Reference number: NI-ADIUM-NI-0073-20250822 (0)) on 22-Aug-2025 from a consumer (non-healthcare professional) regarding a child, 8-year-old female patient who experienced non-serious events of ''Frequent mood swings" (Mood altered) and "8-year-old female patient being treated with Eligard 22.5mg for 3 months for precocious puberty" (Off label use) during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 25-Aug-2025.

The patient's medical history was unknown and current condition included precocious puberty.

Concomitant medications were not reported.

On 23-May-2025, the patient began getting treated with Eligard 22.5 mg, every 3 months, via subcutaneous route, for precocious puberty (Lot numbers and Expiration dates were not provided).

On an unknown date in July-2025, the patient experienced frequent mood swings. No further information was available.

Corrective treatment was not reported.

Action taken with Eligard in response to the events was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of mood altered was not recovered and off label use was unknown.

The reporter did not assess the seriousness of mood altered and off label use.

The reporter assessed the causality of mood altered and off label use in relationship to Eligard and Eligard unspecified device as related.

No further queries were raised.

Listedness
mood altered >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
mood altered> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
mood altered> Eligard®>unlisted as per USPI Eligard®>Feb-2025
mood altered> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Off label use>Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Off label use> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Off label use> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Off label use> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding a child, 8-year-old female patient who experienced Mood altered (Frequent mood swings) and Off label use (8-year-old female patient being treated with Eligard 22.5mg for 3 months for precocious puberty) during Eligard (leuprolide acetate) 22.5 mg therapy for precocious puberty. Tolmar assessed the reported events as non-serious since they did not meet the ICH seriousness criteria. The causal role of rug component of Eligard(not related to device) was assessed as related event mood altered considering the close temporality. Age group of the patient could also be confounder for the event. The causality of event off label use was assessed as not related to suspect Eligard(drug and device) as the event occurred with the product due to human action rather than due to drug.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	:	Eligard® (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
Lot Number	:	1) Unknown 2) Unknown
Daily Dose	:	(22.5 milligram(s), 1 in 3 Month) (22.5 milligram(s))
Route of Admin	:	1) Subcutaneous 2) Subcutaneous

Continuation Sheet for CIOMS report

Indications : 1) Precocious puberty [10058084 - Precocious puberty]
Therapy Dates : 1) From : 23/May/2025 To :Continuing
Action(s) Taken With Drug : Dose not changed

Causality

1) Frequent mood swings (Altered mood - 10001850, Mood altered - 10027940)
Causality as per reporter : Related
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) 8-year-old female patient being treated with Eligard 22.5mg for 3 months for precocious puberty (Off label use in unapproved indication - 10084345, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Frequent mood swings
CORE UnLabeled
2) 8-year-old female patient being treated with Eligard 22.5mg for 3 months for precocious puberty
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Precocious puberty [10058084 - Precocious puberty]
Action(s) Taken With Drug : Not applicable

Causality

1) Frequent mood swings (Altered mood - 10001850, Mood altered - 10027940)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) 8-year-old female patient being treated with Eligard 22.5mg for 3 months for precocious puberty (Off label use in unapproved indication - 10084345, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Frequent mood swings
CORE
2) 8-year-old female patient being treated with Eligard 22.5mg for 3 months for precocious puberty
CORE